DANIMER SCIENTIFIC, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7797 USD | +6.37% |
|
+15.07% | -23.56% |
| May. 22 | Jefferies Downgrades Danimer Scientific to Hold From Buy | MT |
| May. 20 | Danimer Scientific Says CEO Steve Croskrey Retiring | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,015 | 854.9 | 181.5 | 104.1 | 90.79 | - | - |
| Enterprise Value (EV) 1 | 1,694 | 829.7 | 181.5 | 104.1 | 90.79 | 90.79 | 90.79 |
| P/E ratio | - | -17.5 x | -1.34 x | -0.89 x | -0.88 x | -1.42 x | -1.27 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 42.6 x | 14.6 x | 3.41 x | 2.23 x | 1.23 x | 0.63 x | 0.36 x |
| EV / Revenue | 42.6 x | 14.6 x | 3.41 x | 2.23 x | 1.23 x | 0.63 x | 0.36 x |
| EV / EBITDA | -626 x | -37.9 x | -4.03 x | -2.67 x | -3.1 x | 17.8 x | 5.66 x |
| EV / FCF | -38.7 x | -3.44 x | -0.8 x | -1.39 x | -1.13 x | -0.42 x | - |
| FCF Yield | -2.58% | -29.1% | -125% | -72% | -88.5% | -238% | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 85,725 | 100,344 | 101,389 | 102,035 | 116,443 | - | - |
| Reference price 2 | 23.51 | 8.520 | 1.790 | 1.020 | 0.7797 | 0.7797 | 0.7797 |
| Announcement Date | 3/29/21 | 2/28/22 | 3/28/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 47.33 | 58.75 | 53.22 | 46.7 | 73.96 | 144.8 | 249.5 |
| EBITDA 1 | -3.218 | -22.58 | -44.99 | -38.99 | -29.3 | 5.091 | 16.03 |
| EBIT 1 | -11.96 | -99.47 | -187.4 | -125.6 | -64.26 | -29.86 | -29.3 |
| Operating Margin | -25.28% | -169.32% | -352.2% | -268.99% | -86.88% | -20.61% | -11.74% |
| Earnings before Tax (EBT) 1 | - | -73.34 | -180.6 | -155.2 | -98.7 | -66.41 | -83.35 |
| Net income 1 | - | -60.11 | -179.8 | -155.5 | -98.7 | -66.41 | -83.35 |
| Net margin | - | -102.31% | -337.78% | -332.92% | -133.44% | -45.85% | -33.4% |
| EPS 2 | - | -0.4875 | -1.335 | -1.140 | -0.8850 | -0.5475 | -0.6150 |
| Free Cash Flow 1 | -52.06 | -248.4 | -226.3 | -74.95 | -80.34 | -216.5 | - |
| FCF margin | -110% | -422.77% | -425.28% | -160.49% | -108.62% | -149.46% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/29/21 | 2/28/22 | 3/28/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 17.73 | 14.74 | 12.7 | 10.45 | 15.32 | 11.93 | 12.86 | 10.95 | 10.9 | 10.22 | 8.981 | 13.4 | 22.92 | 28.25 | 34.35 |
| EBITDA 1 | -10.18 | -10.6 | -12.87 | -12.94 | -8.569 | -8.852 | -10.22 | -9.252 | -10.67 | -8.661 | -7.32 | -9.188 | -4.901 | -2.18 | 0.3077 |
| EBIT 1 | -35.28 | -30.69 | -32.12 | -94.91 | -29.72 | -32.23 | -31.12 | -31.24 | -31.03 | -18.52 | -15.76 | -17.66 | -13.42 | -11.03 | -8.637 |
| Operating Margin | -199% | -208.16% | -252.85% | -908.37% | -193.94% | -270.22% | -241.9% | -285.34% | -284.7% | -181.16% | -175.43% | -131.83% | -58.54% | -39.05% | -25.15% |
| Earnings before Tax (EBT) 1 | -14.26 | -26.68 | -30.68 | -95.11 | -28.09 | -36.73 | -39.3 | -39.69 | -39.43 | -27.26 | -24.64 | -26.94 | -21.4 | -19.51 | -17.42 |
| Net income 1 | -12.45 | -26.39 | -30.44 | -94.88 | -28.05 | -36.64 | -39.24 | -40.16 | -39.43 | -27.26 | -24.64 | -26.94 | -21.4 | -19.51 | -17.42 |
| Net margin | -70.21% | -178.97% | -239.67% | -908.08% | -183.05% | -307.22% | -305.02% | -366.82% | -361.78% | -266.66% | -274.3% | -201.08% | -93.37% | -69.08% | -50.71% |
| EPS 2 | -0.0900 | -0.1950 | -0.2250 | -0.7050 | -0.2100 | -0.2700 | -0.2850 | -0.2925 | -0.2925 | -0.1950 | -0.2300 | -0.2200 | -0.1875 | -0.1667 | -0.1467 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/10/22 | 8/9/22 | 11/8/22 | 3/28/23 | 5/10/23 | 8/8/23 | 11/14/23 | 3/20/24 | 5/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | 321 | 25.2 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -52.1 | -248 | -226 | -74.9 | -80.3 | -216 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | -0.4600 | -0.3500 | -1.000 | -2.900 | - |
| Capex 1 | - | 185 | 164 | 27.7 | 9.04 | 195 | - |
| Capex / Sales | - | 315.6% | 309.08% | 59.28% | 12.22% | 134.29% | - |
| Announcement Date | 3/29/21 | 2/28/22 | 3/28/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
0.7797
USD
Average target price
1.41
USD
Spread / Average Target
+80.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.56% | 90.79M | |
| +5.09% | 40.53B | |
| -29.56% | 19.26B | |
| -17.55% | 12.78B | |
| -6.25% | 10.11B | |
| -15.09% | 9.51B | |
| +16.17% | 8.03B | |
| +6.84% | 6.67B | |
| -30.36% | 5.29B | |
| -26.17% | 3.47B |
- Stock Market
- Equities
- DNMR Stock
- Financials Danimer Scientific, Inc.
